Floatz logo

Granisetron

Stage IIA Fallopian Tube Cancer

Gynecologic Oncology GroupSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

125 Active assets in the Stage IIA Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Granisetron is also rated in:

cancer of unknown primary siteDormant
BB
Indicative ·
71 / 100
View asset →
myofascial pain syndromeDormant
BB
Indicative ·
69 / 100
View asset →
temporomandibular joint disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →